981 results on '"Noy, Ariela"'
Search Results
2. Limited stage high grade B-cell lymphoma with MYC, BCL2 and/or BCL6 rearrangements: BCL2 rearrangements drives the poor outcomes
3. Author Correction: Duvelisib plus romidepsin in relapsed/refractory T cell lymphomas: a phase 1b/2a trial
4. Factors Affecting Diagnostic Yield of Lesional Bone Biopsy in Hematologic Malignancy Patients
5. CD5 expression in marginal zone lymphoma does not predict inferior outcome and has similarities to indolent lymphomas
6. Matched control analysis suggests that R-CHOP followed by (R)-ICE may improve outcome in non-GCB DLBCL compared with R-CHOP
7. Correction to: Factors Affecting Diagnostic Yield of Lesional Bone Biopsy in Hematologic Malignancy Patients
8. Patients with Castleman disease report mild COVID-19 symptoms and mount a humoral response to SARS-CoV-2 vaccination
9. Retrospective characterization of nodal marginal zone lymphoma
10. TP53 mutations identify high-risk events for peripheral T-cell lymphoma treated with CHOP-based chemotherapy
11. Brentuximab vedotin with AVD for stage II–IV HIV-related Hodgkin lymphoma (AMC 085): phase 2 results from an open-label, single arm, multicentre phase 1/2 trial
12. Primary lymphoma of the breast: A report of two cases.
13. Predictors of survival in patients with MALT lymphoma: a retrospective, case-control study
14. Genetic subgroups inform on pathobiology in adult and pediatric Burkitt lymphoma
15. Zanubrutinib, obinutuzumab, and venetoclax with minimal residual disease-driven discontinuation in previously untreated patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: a multicentre, single-arm, phase 2 trial
16. Involved-site radiotherapy for Helicobacter pylori–independent gastric MALT lymphoma: 26 years of experience with 178 patients
17. Active surveillance of primary extranodal marginal zone lymphoma of bronchus-associated lymphoid tissue
18. Clinical characteristics and outcomes of extranodal stage I diffuse large B-cell lymphoma in the rituximab era
19. Durable ibrutinib responses in relapsed/refractory marginal zone lymphoma: long-term follow-up and biomarker analysis
20. Outcomes in patients with DLBCL treated with commercial CAR T cells compared with alternate therapies
21. HIV-associated Burkitt lymphoma
22. Extra copies of MYC, BCL2, and BCL6 and outcome in patients with diffuse large B-cell lymphoma
23. Castleman disease patients report mild COVID-19 symptoms and mount a humoral response to SARS-CoV-2 vaccination
24. Risk of Cancer among Commercially Insured HIV-Infected Adults on Antiretroviral Therapy.
25. Clinical outcomes with use of radiation therapy and risk of transformation in early-stage follicular lymphoma
26. Allogeneic Hematopoietic Cell Transplant for HIV Patients with Hematologic Malignancies: The BMT CTN-0903/AMC-080 Trial
27. Optimizing treatment of HIV-associated lymphoma
28. Correction to: Factors Affecting Diagnostic Yield of Lesional Bone Biopsy in Hematologic Malignancy Patients
29. Factors Affecting Diagnostic Yield of Lesional Bone Biopsy in Hematologic Malignancy Patients
30. Gemcitabine plus pembrolizumab after checkpoint blockade failure as a strategy in multiply relapsed Hodgkin lymphoma
31. Dose-adjusted EPOCH-R (etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab) in untreated aggressive diffuse large B-cell lymphoma with MYC rearrangement: a prospective, multicentre, single-arm phase 2 study
32. Safety and Preliminary Efficacy of Vorinostat With R-EPOCH in High-risk HIV-associated Non-Hodgkin's Lymphoma (AMC-075)
33. Rosai-Dorfman Disease—Utility of 18F-FDG PET/CT for Initial Evaluation and Follow-up
34. Prognostic factors for adult patients with Burkitt lymphoma treated with dose-adjusted EPOCH-R
35. Diffuse large B-cell lymphoma involving osseous sites: utility of response assessment by PET/CT and good long-term outcomes
36. TP53mutations identify high-risk events for peripheral T-cell lymphoma treated with CHOP-based chemotherapy
37. P1220: EXPLORING TP53 BIOLOGY IN DIFFUSE LARGE B-CELL LYMPHOMA: A GENOMIC AND TRANSCRIPTOMIC META-ANALYSIS
38. Brentuximab vedotin with AVD for stage II–IV HIV-related Hodgkin lymphoma (AMC 085): phase 2 results from an open-label, single arm, multicentre phase 1/2 trial
39. Burkitt Lymphoma
40. Prognostic significance of baseline metabolic tumor volume in relapsed and refractory Hodgkin lymphoma
41. Targeting Bruton tyrosine kinase with ibrutinib in relapsed/refractory marginal zone lymphoma
42. Follicular lymphoma in the modern era: survival, treatment outcomes, and identification of high-risk subgroups
43. Gemcitabine plus pembrolizumab after checkpoint blockade failure as a strategy in multiply relapsed Hodgkin lymphoma.
44. HIV Lymphoma and Burkitts Lymphoma
45. The efficacy of tixagevimab–cilgavimab prophylaxis against Omicron BA.5 variants in patients with hematological malignancies: insights from the Leukemia and Lymphoma Society Registry
46. Predictors of SARS-CoV-2 Omicron breakthrough infection after receipt of AZD7442 (tixagevimab-cilgavimab) for pre-exposure prophylaxis among hematologic malignancy patients
47. Supplementary Methods, Supplementary Tables 1 through 7, and Supplementary Figures 1 through 7 from Ibrutinib Unmasks Critical Role of Bruton Tyrosine Kinase in Primary CNS Lymphoma
48. Data from Ibrutinib Unmasks Critical Role of Bruton Tyrosine Kinase in Primary CNS Lymphoma
49. Brentuximab vedotin and AVD followed by involved-site radiotherapy in early stage, unfavorable risk Hodgkin lymphoma
50. Autologous hematopoietic cell transplantation for HIV-related lymphoma: results of the BMT CTN 0803/AMC 071 trial
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.